Rocha Vanderson, Ruggeri Annalisa, Spellman Stephen, Wang Tao, Sobecks Ronald, Locatelli Franco, Askar Medhat, Michel Gerard, Arcese William, Iori Anna Paola, Purtill Duncan, Danby Robert, Sanz Guillermo F, Gluckman Eliane, Eapen Mary
Eurocord, Hôpital Saint Louis, Paris, France; Churchill Hospital and NHSBT, University of Oxford, Oxford, United Kingdom.
Eurocord, Hôpital Saint Louis, Paris, France; Service d'Hematologie et therapie cellulaire, Hôpital Saint Antoine, Paris, France.
Biol Blood Marrow Transplant. 2016 Jul;22(7):1284-1289. doi: 10.1016/j.bbmt.2016.04.007. Epub 2016 Apr 16.
The effect of killer cell immunoglobulin-like receptor (KIR)-ligand matching on outcomes after unrelated cord blood (CB) transplantation was studied in 461 patients with acute myeloid leukemia, categorizing KIR ligand for HLA-C groups C1 and C2 and Bw4. Donor-recipient HLA matching considered allele-level matching at HLA-A, -B, -C, and -DRB1. Separate analyses were conducted for 6-7/8 HLA-matched and 3-5/8 HLA-matched transplants because HLA matching confounded KIR-ligand matching (ie, KIR-ligand mismatching was less likely with better HLA matching). All patients received single CB unit and myeloablative conditioning. There were no significant differences in nonrelapse mortality (NRM), relapse, and overall mortality by KIR-ligand match status. However, among recipients of 3-5/8 HLA-matched transplants, NRM (HR, 2.26; P = .008) and overall mortality (HR, 1.78; P = .008) but not relapse were higher with KIR-ligand mismatched (host-versus-graft direction) compared with KIR-ligand matched transplants. These data do not support selecting CB units based on KIR-ligand match status for transplants mismatched at 1 or 2 HLA loci. Although transplants mismatched at 3 or more HLA loci are not recommended, avoiding KIR-ligand mismatching in this setting lowers mortality risks.
在461例急性髓系白血病患者中,研究了杀伤细胞免疫球蛋白样受体(KIR)配体匹配对非亲缘脐血(CB)移植后结局的影响,将KIR配体分为HLA-C的C1和C2组以及Bw4。供受者HLA匹配考虑了HLA-A、-B、-C和-DRB1的等位基因水平匹配。由于HLA匹配混淆了KIR配体匹配(即HLA匹配越好,KIR配体错配的可能性越小),因此对6-7/8 HLA匹配和3-5/8 HLA匹配的移植进行了单独分析。所有患者均接受单个CB单位和清髓性预处理。根据KIR配体匹配状态,非复发死亡率(NRM)、复发率和总死亡率无显著差异。然而,在3-5/8 HLA匹配移植的受者中,与KIR配体匹配的移植相比,KIR配体错配(宿主对移植物方向)的NRM(风险比[HR],2.26;P = 0.008)和总死亡率(HR,1.78;P = 0.008)更高,但复发率无差异。这些数据不支持在1或2个HLA位点不匹配的移植中根据KIR配体匹配状态选择CB单位。虽然不建议进行在3个或更多HLA位点不匹配的移植,但在这种情况下避免KIR配体错配可降低死亡风险。